Drug Trial Radar · NCT06534502
Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Azurity PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research is to determine the optimal dose, safety and tolerability of zonisamide oral suspension in children ages 1 month to 17 years of age who have partial-onset (focal) seizures. The study consists of four periods: a Screening Period (about 14 days), a Titration Period (8 weeks), a Maintenance Period (4 weeks), and a Follow-Up Period (1 week).
Conditions
- Seizures
- Seizures, Focal
- Seizure, Partial Onset
- Seizure Disorder, Partial
- Seizure, Partial
- Epilepsies, Partial
- Epilepsy
Interventions
Zonisamide Oral ProductDrug
Zonisamide oral suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentration of serum zonisamideTime frame: Up to 15 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Le Bonheur Children's Hospital
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.